Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine in chronic glaucoma
NCT00141882Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 1999
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of memantine in open-angle glaucoma (OAG), sponsored by Allergan. Primary endpoint: Glaucomatous Visual Field Progression by Standard Automated Perimetry at 48 months. Started Mar 1999; status: completed.
02
Drugs
memantine
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT00141882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141882.